VR Adviser’s Dianthus Therapeutics DNTH Stock Holding History

VR Adviser’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115M	Hold	1,180,000	–	–	3.49%	5
2026 Q1	$99M	Buy	1,180,000 +180,000	+18%	+$10.4M	3.7%	6
2025 Q4	$41.2M	Buy	1,000,000 +39,197	+4%	+$1.52M	2.04%	17
2025 Q3	$37.8M	Sell	960,803 -39,197	-4%	-$1M	2.13%	16
2025 Q2	$18.6M	Sell	1,000,000 -744,373	-43%	-$14M	1.4%	20
2025 Q1	$31.6M	Hold	1,744,373	–	–	2.69%	12
2024 Q4	$38M	Hold	1,744,373	–	–	2.61%	13
2024 Q3	$47.8M	Sell	1,744,373 -350,000	-17%	-$9.75M	2.5%	12
2024 Q2	$54.2M	Hold	2,094,373	–	–	3.45%	10
2024 Q1	$62.8M	Buy	2,094,373 +1,166,667	+126%	+$25.4M	2.99%	10
2023 Q4	$9.65M	Hold	927,706	–	–	0.66%	28
2023 Q3	$12.7M	Buy	+927,706	New	+$11.7M	1.34%	24

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

VR Adviser's DNTH Position: Q2 2026 in Review

VR Adviser held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 1,180,000 shares worth $115M. The position accounts for 3.49% of the portfolio, ranked #5.

VR Adviser first reported a position in DNTH in Q3 2023 and has held it in 12 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

VR Adviser held 1,180,000 shares of Dianthus Therapeutics worth $115M as of Q2 2026.
VR Adviser left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 3.49% of VR Adviser's portfolio in Q2 2026, its #5 holding.
VR Adviser first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 12 quarters since.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.